AstraZeneca and AI Sweden are challenging the AI community to solve the problem of labeling cell images without requiring toxic preprocessing of cell cultures.
The task is to utilize machine learning to combine the advantages of bright field and fluorescence imaging and at the same time avoid the toxic effects of cell labeling by predicting the content of the fluorescence images from the corresponding bright field images.
This challenge will help AstraZeneca to accelerate the drug development process. The solutions will be used by AstraZeneca scientists to treat failing hearts, fibrotic lungs, diabetes, liver diseases, neurodegeneration and cancer.
The selected teams will get access to world leading computational infrastructure from AI Sweden and guidance from researchers at AstraZeneca during the entire challenge. On November 2, the teams will get access to the data.